Quick Answer
RELMADA THERAPEUTICS, INC. reported Stockholders Equity of $86.51 million for fiscal year 2025.
RELMADA THERAPEUTICS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $86.51M | +143.5% |
| 2024 | $35.52M | -58.4% |
| 2023 | $85.36M | -39.2% |
| 2022 | $140.44M | -32.6% |
| 2021 | $208.26M | +97.3% |
| 2020 | $105.58M | -8.7% |
| 2019 | $115.68M | +1419.4% |
| 2019 | $7.61M | +238.1% |
| 2018 | -$5.51M | -477.5% |
| 2017 | $1.46M | -79.3% |
| 2016 | $7.04M | -20.1% |
| 2015 | $8.81M | +894.4% |
| 2014 | -$1.11M | +93.8% |
| 2013 | -$17.95M | -131329.0% |
| 2013 | -$13.7K | +99.6% |
| 2012 | -$3.71M | -32775.8% |
| 2012 | $11.4K | +14.6% |
| 2011 | $9.9K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.47M | -80.1% | -40.7% |
| June 30, 2025 | $15.95M | -74.1% | -28.9% |
| March 31, 2025 | $22.44M | -68.9% | -36.8% |
| December 31, 2024 | $35.52M | -58.4% | -25.4% |
| September 30, 2024 | $47.63M | -52.7% | -22.6% |
| June 30, 2024 | $61.49M | -44.8% | -14.6% |
| March 31, 2024 | $72.05M | -42.6% | -15.6% |
| December 31, 2023 | $85.36M | -39.2% | -15.3% |
- RELMADA THERAPEUTICS, INC. showed an increase of +143.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, RELMADA THERAPEUTICS, INC.’s stockholders equity has grown by 872876.9% (from $9.9 thousand to $86.51 million).
- The most recent figure is from RELMADA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: